Sacramento, CA—(ENEWSPF)— As the first and only state contracting for its own affordable insulin, Governor Gavin Newsom today announced that CalRx® biosimilar insulin glargine pens will be available to consumers in California beginning January 1, 2026. This launch marks a significant step in the state’s ongoing effort to lower prescription drug prices and improve medication access statewide.
Through an agreement secured by Civica Rx — a nonprofit generic drug manufacturer — with Biocon Biologics, Californians will have access to an interchangeable biosimilar insulin glargine pen. These will be offered under the CalRx brand and pricing.
